Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma

NCT02360579 is registered in ClinicalTrials.gov with Iovance Biotherapeutics, Inc. as lead sponsor.

NCT NCT02360579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02360579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma
Lead sponsor
Iovance Biotherapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 24, 2015
Completion date
October 24, 2024
Enrollment
220 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma